ERBB2 and non-small cell lung carcinoma: The HER2 antibody trastuzumab [10] or lapatinib, a dual EGFR-erbB2 TKI, as well as other tyrosine kinase inhibitors [11] in breast cancer, the epidermal growth factor inhibitors gefitinib and erlotinib in non-small cell lung cancer [12,13] or the BRAF inhibitor vemurafenib in melanoma [14] exemplify the efficacy of targeted agents.